Edwards Lifesciences’ (EW) Buy Rating Reaffirmed at BTIG Research

Edwards Lifesciences (NYSE:EW)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research note issued to investors on Friday, Benzinga reports. They currently have a $110.00 price objective on the medical research company’s stock. BTIG Research’s price objective points to a potential upside of 26.88% from the company’s current price.

Other equities research analysts have also issued reports about the company. Mizuho upped their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Truist Financial lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. UBS Group started coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $86.69 on Friday. The firm has a 50-day simple moving average of $89.36 and a 200-day simple moving average of $85.80. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.92 billion, a price-to-earnings ratio of 49.82, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 5,045 shares of company stock valued at $457,749. 0.31% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently modified their holdings of the business. Rehmann Capital Advisory Group lifted its holdings in shares of Edwards Lifesciences by 2.1% in the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after buying an additional 130 shares in the last quarter. Quadrant Capital Group LLC grew its stake in Edwards Lifesciences by 0.9% during the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after acquiring an additional 136 shares in the last quarter. Stephens Inc. AR grew its stake in Edwards Lifesciences by 5.4% during the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after acquiring an additional 144 shares in the last quarter. Aspen Investment Management Inc increased its holdings in Edwards Lifesciences by 1.5% during the 4th quarter. Aspen Investment Management Inc now owns 10,381 shares of the medical research company’s stock worth $885,000 after acquiring an additional 150 shares during the period. Finally, NorthRock Partners LLC increased its holdings in Edwards Lifesciences by 1.0% during the 2nd quarter. NorthRock Partners LLC now owns 16,191 shares of the medical research company’s stock worth $1,465,000 after acquiring an additional 153 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.